The Assault on Drug Innovation

But elite opinion matches the public’s and is now targeting other medicines, such as the new class of monoclonal antibodies called PCSK9 inhibitors that lower bad LDL cholesterol to levels that statins can’t achieve, with no side effects. Cancer drugs … http://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=5F24679DCBB54526A8A11BE033B9ED3F&url=http%3a%2f%2fwww.wsj.com%2farticles%2fthe-assault-on-drug-innovation-1442964103%3fmod%3drss_opinion_main&c=D0ANQk9Ax3_JaajSZXajq_HqKaXDdGQ_wPctns5NvWg&mkt=en-us